BACKGROUND: A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer. This protocol provides a mechanism to effect a variety of such studies. OBJECTIVES: Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from patients with HIV infection, KSHV infection, or with cancer. ELIGIBILITY: Eligibility criteria include age 18 years or older and at lest one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion. DESIGN: Blood samples may be collected at the initial visit, and at follow-up visits. Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the patients. Specific risks will be described in a separate consent to be obtained at the time of the biopsy. Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators. ...

Population

Primary Clinical

Brief Title

Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

Official Title

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer

Brief Summary

BACKGROUND: A number of important scientific advances can be made through the study of blood, <br /> bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with <br /> Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or <br /> cancer. This protocol provides a mechanism to effect a variety of such studies. <br /> <br /> OBJECTIVES: Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue <br /> samples from patients with HIV infection, KSHV infection, or with cancer. <br /> <br /> ELIGIBILITY: Eligibility criteria include age 18 years or older and at lest one of the <br /> following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV <br /> seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with <br /> appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion. <br /> <br /> DESIGN: Blood samples may be collected at the initial visit, and at follow-up visits. Tumor <br /> samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, <br /> by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal <br /> risk to the patients. Specific risks will be described in a separate consent to be obtained <br /> at the time of the biopsy. Samples will be studied in the HIV and AIDS Malignancy Branch, <br /> CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators. <br /> <br /> ...

Detailed Description

BACKGROUND:

A number of important scientific advances can be made through the study of blood, bone
marrow, tumor, or other tissue samples from patients with HIV infection, infection with
Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or
cancer.

This protocol provides a mechanism to affect a variety of such studies.

OBJECTIVES:

Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from
patients with HIV infection, KSHV infection, or with cancer.

ELIGIBILITY:

Eligibility criteria include age 18 years or older and at lest one of the following: Exposure
risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1
seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s
sarcoma; or cervical or anal intraepithelial lesion.

DESIGN:

Up to 999 subjects will be enrolled in this study.

Blood samples may be collected at the initial visit, and at follow-up visits.

Other fluids/excretions may be collected (such as urine, saliva, semen, and stool).

Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal
fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with
minimal risk to the patients.

Specific risks will be described in a separate consent to be obtained at the time of the
biopsy.

Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in
NCI-Frederick; or those of collaborating investigators.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.